

20<sup>th</sup> March 2022

## **Wockhardt and Serum Life Sciences UK announce collaboration for manufacturing multiple vaccines in the United Kingdom**

Wockhardt, the global biotechnology major announced today, 20<sup>th</sup> March 2022 a collaboration with Serum Life Sciences UK Ltd, a subsidiary of the Serum Institute of India, one of the world's largest vaccine manufacturers to deliver a global vaccine programme.

This collaboration between a subsidiary of Wockhardt and Serum Life Sciences UK will help create considerable number of employment opportunities along with creation of new sterile fill and finish facility in Wrexham, North Wales ('New Facility'). A profit sharing arrangement has been made between the two parties for this New Facility that will deliver an additional 150 million vaccine doses of multiple vaccines.

The Founder Chairman of Wockhardt Dr. Habil Khorakiwala said, "This collaboration between Serum Life Sciences and Wockhardt UK is testament to the excellence and innovation that both parties bring to the global vaccine market".

Natasha Poonawalla, Chairperson, Serum Life Sciences, added "We are delighted to have formed a strategic partnership between Wockhardt and Serum Life Sciences. The collaboration will be instrumental in building long-term capacity in the UK. With this, we seek to further bolster supply resilience and support the global rollout of vaccines."

Dr Murtaza Khorakiwala, Managing Director and Global CEO of Wockhardt comments: "This deal today signifies the role that we will now step up to play in the global supply of multiple vaccines protecting citizens against infectious diseases – which may include those used to immunise against COVID-19."

Wockhardt UK has manufactured a COVID-19 vaccine in collaboration with UK Government and AstraZeneca. Its collaboration with Serum Life Sciences is an addition to the earlier arrangement.

### **About Wockhardt**

Wockhardt is a research based global Pharmaceutical and Biotech Company, headquartered in India. Wockhardt is employing over 5,000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 82% of its global revenues coming from international businesses. Wockhardt's New Drug Discovery programme has focussed on unmet need of anti-bacterial drugs that are effective against the menace of untreatable superbugs. USFDA has granted QIDP Status (Qualified Infectious Disease Product) for six antibiotics discovered at Wockhardt, three of them are for Gram Negative and other three are for Gram Positive multi-drug resistant "Superbugs".

### **About Serum Life Sciences Ltd**

Serum Life Sciences UK Ltd is a subsidiary company of Serum Institute of India Pvt Ltd. With its global sales office in London, it will market SARS-CoV-2 vaccines manufactured by Serum Institute of India Pvt Ltd. Serum Institute of India Pvt Ltd is developing several SARS-CoV-2 vaccines in partnership, as well as in-house candidates. Serum Life Sciences Ltd is also a leading investor in the UK life sciences sector.

### **Media Enquiries Wockhardt UK**

[media@wockhardt.co.uk](mailto:media@wockhardt.co.uk)

01244 567236

### **Media enquiries Wockhardt HQ India**

[investorrelations@wockhardt.com](mailto:investorrelations@wockhardt.com) / [EFerrao@wockhardt.com](mailto:EFerrao@wockhardt.com)

### **Disclaimer:**

*Wockhardt Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a rights issue of its equity shares and has filed a Letter of Offer. The Letter of Offer is available on the website of SEBI at <https://www.sebi.gov.in>, the website of BSE at <https://www.bseindia.com>, the website of NSE at <https://www.nseindia.com>, the website of the Lead Manager at [www.ambit.co](http://www.ambit.co) and the website of the registrar to the Issue at [www.linkintime.co.in](http://www.linkintime.co.in).*

*Investors should note that investment in equity shares involves a high degree of risk. For details, potential investors should refer to the Letter of Offer, including the section titled "Risk Factors".*